GlassScriptPhysician profile
Bradley D Kleinert
NPI 1629772231
$10,547.68
in general payments reported to CMS, 2019-2025
53 companies · $4,138 in 2025
The $4,138 reported for 2025 was more than what 97% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,301 · 2024: $4,108 · 2025: $4,138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,960 · Education: $1,588.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,959.75 |
| Education | $1,587.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,097.76 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $906.70 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $814.24 | 2023-2025 | Lynparza, Enhertu, Tagrisso |
| Lilly USA, LLC | $657.65 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Exelixis INC. | $575.59 | 2023-2025 | Cabometyx |
| Genentech USA, INC. | $555.14 | 2023-2025 | Polivy, Venclexta, Tecentriq |
| Seagen INC. | $519.83 | 2023-2025 | Tivdak, Tukysa, Padcev |
| Takeda Pharmaceuticals U.S.A., INC. | $506.51 | 2023-2025 | Fruzaqla, Ninlaro, Alunbrig |
| Incyte Corporation | $492.48 | 2023-2025 | Jakafi, Pemazyre, Monjuvi |
| Eisai INC. | $404.60 | 2023-2025 | |
| Daiichi Sankyo INC. | $389.16 | 2023-2025 | Enhertu, Injectafer, Datroway |
| Genzyme Corporation | $317.37 | 2023-2025 | |
| Abbvie INC. | $249.45 | 2023-2025 | |
| Array Biopharma INC | $197.91 | 2023-2025 | Braftovi, Mektovi, Tukysa |
| Pharmacosmos Therapeutics INC. | $183.60 | 2023-2025 | Monoferric, Cosela |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirati Therapeutics, INC. | $177.32 | 2023-2024 | Krazati |
| Celgene Corporation | $157.72 | 2023-2025 | Reblozyl, Pomalyst |
| Deciphera Pharmaceuticals INC. | $142.95 | 2023-2025 | Qinlock, Romvimza |
| Bayer Healthcare Pharmaceuticals INC. | $142.75 | 2023-2025 | |
| Taiho Oncology, INC. | $133.33 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $128.69 | 2023-2025 | |
| Servier Pharmaceuticals LLC | $108.79 | 2024-2025 | |
| Janssen Biotech, INC. | $105.32 | 2023-2024 | Imbruvica, Darzalex, Erleada |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.16 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $99.00 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $98.17 | 2024-2025 | Libtayo, Lynozyfic |
| Beigene USA, INC. | $94.43 | 2023-2024 | Brukinsa, Tevimbra |
| Alexion Pharmaceuticals, INC. | $89.35 | 2024-2025 | Ultomiris |
| Puma Biotechnology, INC. | $88.48 | 2023-2025 | Nerlynx |
| Blueprint Medicines Corporation | $80.38 | 2023-2025 | Ayvakit |
| Amneal Pharmaceuticals LLC | $78.21 | 2023-2025 | Avastin, Neupogen, Neulasta |
| Adaptive Biotechnologies Corporation | $76.45 | 2023 | Clonoseq |
| Aveo Pharmaceuticals, INC. | $65.82 | 2025 | |
| Beone Medicines USA, INC. | $60.44 | 2025 | Brukinsa |
| Tolmar, INC. | $54.66 | 2024-2025 | Rubraca, Eligard |
| Stemline Therapeutics INC. | $54.05 | 2025 | Orserdu |
| Recordati_rare_diseases_inc. | $53.46 | 2024-2025 | Sylvant |
| Kyowa Kirin, INC. | $50.95 | 2023-2024 | Poteligeo |
| Geron Corporation | $48.97 | 2025 | Rytelo |
| Alnylam Pharmaceuticals INC. | $47.09 | 2023-2025 | Givlaari, Amvuttra |
| Emd Serono, INC. | $41.92 | 2023-2025 | Bavencio |
| Pharmaand Gmbh | $40.96 | 2025 | Rubraca |
| Jazz Pharmaceuticals INC. | $36.06 | 2024-2025 | |
| Sobi, INC | $35.92 | 2023-2025 | |
| Tersera Therapeutics LLC | $29.42 | 2025 | Zoladex |
| Caris Mpi, INC. | $25.43 | 2025 | Mi Cancer Seek |
| Springworks Therapeutics, INC. | $25.16 | 2025 | Ogsiveo |
| Sirtex Medical INC | $22.05 | 2023 | Sir-Spheres Microspheres |
| Agios Pharmaceuticals, INC. | $21.10 | 2025 | Pyrukynd |
| Amgen INC. | $18.27 | 2023 | Lumakras, Riabni, Mvasi |
| Astellas Pharma US INC | $17.41 | 2023 | Xospata |
| Novo Nordisk INC | $15.50 | 2024 | Rybelsus, Ozempic |
| Ipsen Biopharmaceuticals, INC | $14.55 | 2024 | Onivyde |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Kleinert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.